Lutetium Lu 177 vipivotide tetraxetan combined with ARPI and ADT improved rPFS in PSMA-positive mHSPC patients compared to ARPI and ADT alone. Lutetium Lu 177 vipivotide tetraxetan significantly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback